Keywords: janssen, astrazeneca, drugs, now, lead, antipsychotics, johnson
Janssen and AstraZeneca drugs now lead antipsychotics
Article | 24 September 2007
Johnson & Johnson subsidiary Janssen's Risperdal (risperidone) and AstraZeneca's Seroquel (quetiapine) have overtaken Eli Lilly's Zyprexa (olanzapine) as the first-line antipsychotics ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
